Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor
AC Seghers, S Wilgenhof, C Lebbé… - Melanoma research, 2012 - journals.lww.com
The v-raf murine sarcoma viral oncogene homolog B1 (BRAF) gene is mutated at position
600 in about 50% of melanoma. Mutant BRAF activates the downstream effectors of the RAS-
RAF-MEK-MAPK pathways and is a driver oncogene in these melanoma cells. Selective
BRAF-V600 inhibitors (vemurafenib, dabrafenib) have high antitumor activity against BRAF-
V600-mutant melanoma with objective tumor response rates. Resistance, however,
develops within less than a year in the majority of patients. Several different mechanisms …
600 in about 50% of melanoma. Mutant BRAF activates the downstream effectors of the RAS-
RAF-MEK-MAPK pathways and is a driver oncogene in these melanoma cells. Selective
BRAF-V600 inhibitors (vemurafenib, dabrafenib) have high antitumor activity against BRAF-
V600-mutant melanoma with objective tumor response rates. Resistance, however,
develops within less than a year in the majority of patients. Several different mechanisms …